{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T19:29:05Z","timestamp":1772220545853,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2008,4,5]],"date-time":"2008-04-05T00:00:00Z","timestamp":1207353600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s10620-007-0003-2","type":"journal-article","created":{"date-parts":[[2008,4,4]],"date-time":"2008-04-04T16:50:05Z","timestamp":1207327805000},"page":"1988-1993","source":"Crossref","is-referenced-by-count":22,"title":["Atorvastatin Does Not Improve Liver Biochemistries or Mayo Risk Score in Primary Biliary Cirrhosis"],"prefix":"10.1007","volume":"53","author":[{"given":"Carmen M.","family":"Stanca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Bach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Allina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Bodian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Henry","family":"Bodenheimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Odin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,4,5]]},"reference":[{"key":"3_CR1","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMra043898","volume":"353","author":"MM Kaplan","year":"2005","unstructured":"Kaplan MM, Gershwin ME (2005) Primary biliary cirrhosis. N Engl J Med 353:1261\u20131273","journal-title":"N Engl J Med"},{"key":"3_CR2","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJM198906293202602","volume":"320","author":"BH Markus","year":"1989","unstructured":"Markus BH, Dickson ER, Grambsch PM, Fleming TR, Mazzaferro V, Klintmalm GB, Wiesner RH, Van Thiel DH, Starzl TE (1989) Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med 320:1709\u20131713","journal-title":"N Engl J Med"},{"key":"3_CR3","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/S0022-2275(20)33328-9","volume":"39","author":"M Puppo Del","year":"1998","unstructured":"Del Puppo M, Kienle MG, Petroni ML, Crosignani A, Podda M (1998) Serum 27-hydroxycholesterol in patients with primary biliary cirrhosis suggests alteration of cholesterol catabolism to bile acids via the acidic pathway. J Lipid Res 39:2477\u20132482","journal-title":"J Lipid Res"},{"key":"3_CR4","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/0016-5085(85)90642-0","volume":"89","author":"CE Jahn","year":"1985","unstructured":"Jahn CE, Schaefer EJ, Taam LA, Hoofnagle JH, Lindgren FT, Albers JJ, Jones EA, Brewer HB Jr (1985) Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 89:1266\u20131278","journal-title":"Gastroenterology"},{"key":"3_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1365-2362.1984.tb02106.x","volume":"14","author":"A Aly","year":"1984","unstructured":"Aly A, Carlson K, Johansson C, Kirstein P, Rossner S, Wallentin L (1984) Lipoprotein abnormalities in patients with early primary biliary cirrhosis. Eur J Clin Invest 14:155\u2013162","journal-title":"Eur J Clin Invest"},{"key":"3_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/BF01307562","volume":"38","author":"A Propst","year":"1993","unstructured":"Propst A, Propst T, Lechleitner M, Hoppichler F, Kathrein H, Vogel W, Judmaier G, Knapp E, Braunsteiner H (1993) Hypercholesterolemia in primary biliary cirrhosis is no risk factor for atherosclerosis. Dig Dis Sci 38:379\u2013380","journal-title":"Dig Dis Sci"},{"key":"3_CR7","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/hep.1840150518","volume":"15","author":"JS Crippin","year":"1992","unstructured":"Crippin JS, Lindor KD, Jorgensen R, Kottke BA, Harrison JM, Murtaugh PA, Dickson ER (1992) Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: What is the risk? Hepatology 15:858\u2013862","journal-title":"Hepatology"},{"key":"3_CR8","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1056\/NEJM199705083361911","volume":"336","author":"U Leonhardt","year":"1997","unstructured":"Leonhardt U, Nather M, Ramadori G (1997) Primary biliary cirrhosis. N Engl J Med 336:1387, discussion 1388","journal-title":"N Engl J Med"},{"key":"3_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/gut.51.2.265","volume":"51","author":"M Longo","year":"2002","unstructured":"Longo M, Crosignani A, Battezzati PM, Squarcia Giussani C, Invernizzi P, Zuin M, Podda M (2002) Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 51:265\u2013269","journal-title":"Gut"},{"key":"3_CR10","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1136\/gut.2005.079814","volume":"55","author":"M Allocca","year":"2006","unstructured":"Allocca M, Crosignani A, Gritti A, Ghilardi G, Gobatti D, Caruso D, Zuin M, Podda M, Battezzati PM (2006) Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut 55:1795\u20131800","journal-title":"Gut"},{"key":"3_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.atherosclerosis.2006.11.036","volume":"194","author":"A Sorokin","year":"2007","unstructured":"Sorokin A, Brown JL, Thompson PD (2007) Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review. Atherosclerosis 194:293\u2013299","journal-title":"Atherosclerosis"},{"key":"3_CR12","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/0016-5085(85)90213-6","volume":"89","author":"E Christensen","year":"1985","unstructured":"Christensen E, Neuberger J, Crowe J, Altman DG, Popper H, Portmann B, Doniach D, Ranek L, Tygstrup N, Williams R (1985) Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology 89:1084\u20131091","journal-title":"Gastroenterology"},{"key":"3_CR13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0016-5085(93)90422-9","volume":"104","author":"M Lombard","year":"1993","unstructured":"Lombard M, Portmann B, Neuberger J, Williams R, Tygstrup N, Ranek L, Ring-Larsen H, Rodes J, Navasa M, Trepo C et al (1993) Cyclosporin a treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 104:519\u2013526","journal-title":"Gastroenterology"},{"key":"3_CR14","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/0168-8278(92)90065-W","volume":"15","author":"HC Mitchison","year":"1992","unstructured":"Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO, James OF (1992) A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol 15:336\u2013344","journal-title":"J Hepatol"},{"key":"3_CR15","first-page":"342","volume":"122","author":"N Bach","year":"1998","unstructured":"Bach N, Thung SN, Schaffner F (1998) The histologic effects of low-dose methotrexate therapy for primary biliary cirrhosis. Arch Pathol Lab Med 122:342\u2013345","journal-title":"Arch Pathol Lab Med"},{"key":"3_CR16","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1053\/gast.1999.0029900400","volume":"117","author":"MT Hendrickse","year":"1999","unstructured":"Hendrickse MT, Rigney E, Giaffer MH, Soomro I, Triger DR, Underwood JC, Gleeson D (1999) Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 117:400\u2013407","journal-title":"Gastroenterology"},{"key":"3_CR17","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1053\/he.2000.5984","volume":"31","author":"EJ Heathcote","year":"2000","unstructured":"Heathcote EJ (2000) Management of primary biliary cirrhosis. The American association for the study of liver diseases practice guidelines. Hepatology 31:1005\u20131013","journal-title":"Hepatology"},{"key":"3_CR18","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJM199509073331003","volume":"333","author":"JA Kobashigawa","year":"1995","unstructured":"Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA et al (1995) Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333:621\u2013627","journal-title":"N Engl J Med"},{"key":"3_CR19","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/82219","volume":"6","author":"B Kwak","year":"2000","unstructured":"Kwak B, Mulhaupt F, Myit S, Mach F (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6:1399\u20131402","journal-title":"Nat Med"},{"key":"3_CR20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.CIR.101.2.207","volume":"101","author":"DJ Maron","year":"2000","unstructured":"Maron DJ, Fazio S, Linton MF (2000) Current perspectives on statins. Circulation 101:207\u2013213","journal-title":"Circulation"},{"key":"3_CR21","first-page":"890","volume":"15","author":"T Kurihara","year":"1993","unstructured":"Kurihara T, Akimoto M, Abe K, Ishiguro H, Niimi A, Maeda A, Shigemoto M, Yamashita K, Yokoyama I, Suzuki Y et al (1993) Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. Clin Ther 15:890\u2013898","journal-title":"Clin Ther"},{"key":"3_CR22","first-page":"1187","volume":"90","author":"T Kamisako","year":"1995","unstructured":"Kamisako T, Adachi Y (1995) Marked improvement in cholestasis and hypercholesterolemia with simvastatin in a patient with primary biliary cirrhosis. Am J Gastroenterol 90:1187\u20131188","journal-title":"Am J Gastroenterol"},{"key":"3_CR23","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S0168-8278(02)00006-5","volume":"36","author":"U Ritzel","year":"2002","unstructured":"Ritzel U, Leonhardt U, Nather M, Schafer G, Armstrong VW, Ramadori G (2002) Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol 36:454\u2013458","journal-title":"J Hepatol"},{"key":"3_CR24","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1161\/01.CIR.0000017634.00171.24","volume":"105","author":"MA Pfeffer","year":"2002","unstructured":"Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, Davis BR, Friedman CP, Braunwald E (2002) Safety and tolerability of pravastatin in long-term clinical trials: prospective pravastatin pooling (ppp) project. Circulation 105:2341\u20132346","journal-title":"Circulation"},{"key":"3_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jhep.2007.02.013","volume":"47","author":"M Ekstedt","year":"2007","unstructured":"Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S (2007) Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 47:135\u2013141","journal-title":"J Hepatol"},{"key":"3_CR26","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1089-3261(03)00024-2","volume":"7","author":"JL Parra","year":"2003","unstructured":"Parra JL, Reddy KR (2003) Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis 7:415\u2013433","journal-title":"Clin Liver Dis"},{"key":"3_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/hep.1840200120","volume":"20","author":"PA Murtaugh","year":"1994","unstructured":"Murtaugh PA, Dickson ER, Van Dam GM, Malinchoc M, Grambsch PM, Langworthy AL, Gips CH (1994) Primary biliary cirrhosis: prediction of short-term survival based on repeated patient visits. Hepatology 20:126\u2013134","journal-title":"Hepatology"},{"key":"3_CR28","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1053\/jhep.2000.19067","volume":"32","author":"WR Kim","year":"2000","unstructured":"Kim WR, Lindor KD, Malinchoc M, Petz JL, Jorgensen R, Dickson ER (2000) Reliability and validity of the niddk-qa instrument in the assessment of quality of life in ambulatory patients with cholestatic liver disease. Hepatology 32:924\u2013929","journal-title":"Hepatology"},{"key":"3_CR29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S0168-8278(00)80385-2","volume":"32","author":"MI Prince","year":"2000","unstructured":"Prince MI, James OF, Holland NP, Jones DE (2000) Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use. J Hepatol 32:368\u2013373","journal-title":"J Hepatol"},{"key":"3_CR30","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1053\/gast.2002.32993","volume":"122","author":"J Goldblatt","year":"2002","unstructured":"Goldblatt J, Taylor PJ, Lipman T, Prince MI, Baragiotta A, Bassendine MF, James OF, Jones DE (2002) The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology 122:1235\u20131241","journal-title":"Gastroenterology"},{"key":"3_CR31","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/j.1572-0241.2005.41315.x","volume":"100","author":"CM Stanca","year":"2005","unstructured":"Stanca CM, Bach N, Krause C, Tandon N, Freni MA, Gutierrez JA, Bodian C, Lopez J, Berk PD, Bodenheimer HC Jr, Branch AD, Odin JA (2005) Evaluation of fatigue in U.S. patients with primary biliary cirrhosis. Am J Gastroenterol 100:1104\u20131109","journal-title":"Am J Gastroenterol"},{"key":"3_CR32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/00002018-200225090-00004","volume":"25","author":"M Evans","year":"2002","unstructured":"Evans M, Rees A (2002) Effects of hmg-coa reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 25:649\u2013663","journal-title":"Drug Saf"},{"key":"3_CR33","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1136\/gut.2005.080317","volume":"55","author":"DE Jones","year":"2006","unstructured":"Jones DE, Bhala N, Burt J, Goldblatt J, Prince M, Newton JL (2006) Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut 55:536\u2013541","journal-title":"Gut"},{"key":"3_CR34","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.dld.2006.04.013","volume":"38","author":"AT Clarke","year":"2006","unstructured":"Clarke AT, Mills PR (2006) Atorvastatin associated liver disease. Dig Liver Dis 38:772\u2013777","journal-title":"Dig Liver Dis"},{"key":"3_CR35","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.cgh.2006.03.014","volume":"4","author":"S Khorashadi","year":"2006","unstructured":"Khorashadi S, Hasson NK, Cheung RC (2006) Incidence of statin hepatotoxicity in patients with hepatitis c. Clin Gastroenterol Hepatol 4:902\u2013907, quiz 806","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3_CR36","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.amjcard.2005.06.071","volume":"96","author":"K Gibson","year":"2005","unstructured":"Gibson K, Rindone JP (2005) Experience with statin use in patients with chronic hepatitis c infection. Am J Cardiol 96:1278\u20131279","journal-title":"Am J Cardiol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-007-0003-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-007-0003-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-007-0003-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-007-0003-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T07:14:30Z","timestamp":1630998870000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-007-0003-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,5]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["3"],"URL":"https:\/\/doi.org\/10.1007\/s10620-007-0003-2","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,5]]}}}